Novel human evidence for KLKB1 editing
The study extends systemic in vivo CRISPR-Cas9 treatment to a new target and disease, demonstrating sustained dose-dependent reductions in total plasma kallikrein.
↳ Results, Pharmacodynamics; Figure 1
Abstract
BACKGROUND: ), with the goal of lifelong control of angioedema attacks after a single dose. METHODS: In this phase 1 dose-escalation portion of a combined phase 1-2 trial of NTLA-2002 in adults with hereditary angioedema, we administered NTLA-2002 at a single dose of 25 mg, 50 mg, or 75 mg. The primary end points were the safety and side-effect profile of NTLA-2002 therapy. Secondary and exploratory end points included pharmacokinetics, pharmacodynamics, and clinical efficacy determined on the basis of investigator-confirmed angioedema attacks. RESULTS: Three patients received 25 mg of NTLA-2002, four received 50 mg, and three received 75 mg. At all dose levels, the most common adverse events were infusion-related reactions and fatigue. No dose-limiting toxic effects, serious adverse events, grade 3 or higher adverse events, or clinically important laboratory findings were observed after the administration of NTLA-2002. Dose-dependent reductions in the total plasma kallikrein protein level were observed between baseline and the latest assessment, with a mean percentage change of -67% in the 25-mg group, -84% in the 50-mg group, and -95% in the 75-mg group. The mean percentage change in the number of angioedema attacks per month between baseline and weeks 1 through 16 (primary observation period) was -91% in the 25-mg group, -97% in the 50-mg group, and -80% in the 75-mg group. Among all the patients, the mean percentage change in the number of angioedema attacks per month from baseline through the latest assessment was -95%. CONCLUSIONS: In this small study, a single dose of NTLA-2002 led to robust, dose-dependent, and durable reductions in total plasma kallikrein levels, and no severe adverse events were observed. In exploratory analyses, reductions in the number of angioedema attacks per month were observed at all dose levels. (Funded by Intellia Therapeutics; ClinicalTrials.gov number, NCT05120830.).
Key Claims
Primary findingSupported
a single dose of NTLA-2002 led to robust, dose-dependent, and durable reductions in total plasma kallikrein levels, and no severe adverse events were observed
Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
objective pharmacodynamic changes and observed short-term safety in only ten patients with unequal follow-up
Abstract, Conclusions
SecondaryTentative
The mean percentage change in the number of angioedema attacks per month from baseline through the latest assessment was -95%
uncontrolled open-label attack assessment with concomitant prophylaxis and only nine patients contributing percentage changes
Abstract, Results; Table 3
SecondarySupported
Patients who discontinued concomitant long-term prophylaxis continued to have well-controlled disease
descriptive post-withdrawal observations in six patients without randomized withdrawal or a concurrent control
Discussion, p. 438; Figure 2
Derived from the full evaluation — not a separate score.
Strengths · Limitations
Strengths
Systematic early-phase safety assessment
Adverse events were graded using CTCAE v5.0, with laboratory, electrocardiographic, immunogenicity, and dose-limiting-toxicity monitoring reported across all treated patients.
↳ Methods, Clinical Assessments and Study End Points; Results, Safety; Table 2
Limitations inform the next trial
The Discussion connects absent placebo control, concomitant prophylaxis, ascertainment differences, and limited follow-up to uncertainty, then explains how phase 2 washout and randomization address attribution.
↳ Discussion, pp. 439–440
Limitations
Clinical efficacy remains uncontrolled and subjective
Attack reductions come from an open-label, single-group study using electronic diaries and unblinded investigator confirmation, leaving expectation, ascertainment, and temporal effects unresolved.
↳ Methods, Study Design and Oversight and Clinical Assessments
Concomitant prophylaxis complicates treatment attribution
Six patients continued long-term prophylaxis after dosing, and withdrawal timing was chosen by investigators and patients. Post-withdrawal attack freedom is informative but does not isolate the treatment effect.
↳ Results, Angioedema Attacks; Figure 2; Discussion, pp. 439–440
Tiny homogeneous cohort limits generalization
Only ten adults were treated, all identified as White, with follow-up varying by dose cohort. Safety, efficacy, and transferability therefore remain uncertain beyond this narrow sample.
↳ Results, Patients; Table 1
Nabu Commentary
The score reflects a genuine first-in-human advance supported most directly by dose-dependent kallikrein reductions in Figure 1 and systematic short-term safety reporting in Table 2. The phase 1 design is appropriate for dose escalation, but the attack endpoint cannot establish efficacy because the study is open-label, uncontrolled, and permits concomitant prophylaxis. Table 3 and Figure 2 provide encouraging clinical observations, yet the absence of an attack dose-response and discretionary prophylaxis withdrawal constrain causal interpretation. The Discussion handles these limitations substantively and identifies randomization, prophylaxis washout, and long-term follow-up as the appropriate next steps.
Check another paper
Author Note / Field Feedback
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Dimension breakdown
Study Quality
Sound3.7
Confidence highContribution
4.0
The study meaningfully extends in vivo CRISPR editing to KLKB1 and hereditary angioedema, reporting new human safety and pharmacodynamic evidence. Its contribution remains an early clinical demonstration rather than resolution of efficacy or durability.
Introduction, final paragraph; Results, Pharmacodynamics; Discussion, final paragraph
“These results support the continued investigation of NTLA-2002 as a new therapy”
Methodological Rigour
3.3
The registered phase 1 design aligns its primary endpoints with systematic safety monitoring and defined analysis populations. Methodological Rigour is limited by the open-label, uncontrolled attack endpoint, concomitant prophylaxis, and unblinded investigator confirmation of patient diary events.
Methods, Study Design and Oversight, Clinical Assessments, and Statistical Analysis; Discussion, Limitations
“The study does not have a placebo control.”
Reporting
4.1
The paper clearly separates primary safety endpoints from exploratory efficacy and repeatedly states the limitations of sample size, follow-up, and control. Attribution to NTLA-2002 alone after prophylaxis withdrawal is somewhat stronger than the design supports.
Abstract, Conclusions; Discussion, pp. 439–440
“In exploratory analyses, reductions in the number of angioedema attacks per month were observed”
Positioning
4.2
The Discussion relates the findings to established prophylaxis, RNA-silencing evidence, NTLA-2001, and congenital prekallikrein deficiency. Major limitations are connected to their consequences and to design changes in the ongoing phase 2 trial.
Introduction, pp. 433–434; Discussion, pp. 438–440
“The ongoing randomized phase 2 trial requires washout of long-term prophylaxis”
Lower confidence on Contribution, Methodological Rigour — domain match limited.
Reliability
Caveats4 of 4 checks
Internal CoherenceNoted
The principal numerical results are internally consistent, and the paper explicitly reports the absence of a clinical dose-response in attacks. Interpretation of the exploratory attack reductions remains sensitive to ascertainment differences and concomitant prophylaxis.
Research ConductClean
Ethics approval, written consent, independent monitoring, prospective registration, sponsor funding, disclosures, and a data-sharing statement are declared. No location-referenced conduct failure was identified in the supplied text.
Flags: 4 declared / 5 total
Reference IntegrityClean
17 of 17 checkable references verified
17 references in manuscript 1 reference confirmed by manual review
References not verified automatically are resolved manually within 24 hours.
Post-Publication RecordClean
No retraction or expression of concern found in Crossref (includes Retraction Watch).
Last checked: 17 Oct 2026
Sources: Crossref (incl. Retraction Watch) ✓
Readiness
Where this paper’s evidence sits on the path from initial observation to real-world use.
Demonstrated
Human dosing demonstrates short-term safety observations and dose-dependent pharmacodynamic activity, placing the therapy beyond preclinical proof of concept. A ten-person phase 1 study with exploratory efficacy remains far from clinical deployment.
Methods, Study Design and Oversight; Results, Safety and Pharmacodynamics
“a dose-dependent reduction in the total plasma kallikrein protein level was observed”
AI-generated, human-governed. Something look off? Contact us to request a review.